Literature DB >> 33559854

IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Ramesh B Batchu1,2, Oksana V Gruzdyn3,4, Bala K Kolli3,4,5, Rajesh Dachepalli5, Prem S Umar5, Sameer K Rai5, Namrata Singh5, Pavan S Tavva5, Donald W Weaver3, Scott A Gruber3,4.   

Abstract

Unlike other malignancies, ovarian cancer (OC) creates a complex tumor microenvironment with distinctive peritoneal ascites consisting of a mixture of several immunosuppressive cells which impair the ability of the patient's immune system to fight the disease. The poor survival rates observed in advanced stage OC patients and the lack of effective conventional therapeutic options have been attributed in large part to the immature dendritic cells (DCs), IL-10 secreting regulatory T cells, tumor-associated macrophages, myeloid-derived suppressor cells, and cancer stem cells that secrete inhibitory cytokines. This review highlights the critical role played by the intraperitoneal presence of IL-10 in the generation of an immunosuppressive tumor microenvironment. Further, the effect of antibody neutralization of IL-10 on the efficacy of DC and chimeric antigen receptor T-cell vaccines will be discussed. Moreover, we will review the influence of IL-10 in the promotion of cancer stemness in concert with the NF-κB signaling pathway with regard to OC progression. Finally, understanding the role of IL-10 and its crosstalk with various cells in the ascitic fluid may contribute to the development of novel immunotherapeutic approaches with the potential to kill drug-resistant OC cells while minimizing toxic side effects.

Entities:  

Keywords:  CD4+ T cells; CD8+ cytotoxic T cells; Cancer stem cells; Chemokines; Chimeric antigen receptor T cells; Cytokines; Dendritic cells; Epithelial-to-mesenchymal transition; Immunosurveillance; Immunotherapy; Interferon-γ; Interleukin-10; Interleukin-12; Interleukins; Janus kinase-signal transducer and activator of transcription 3 pathway; Mesothelin; Nuclear factor-κB; Ovarian cancer; Regulatory T cells; Transforming growth factor -β; Tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33559854     DOI: 10.1007/978-3-030-55617-4_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  99 in total

Review 1.  Decisions about dendritic cells: past, present, and future.

Authors:  Ralph M Steinman
Journal:  Annu Rev Immunol       Date:  2011-11-17       Impact factor: 28.527

Review 2.  Immune checkpoint inhibition in ovarian cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Ikuo Konishi
Journal:  Int Immunol       Date:  2016-04-07       Impact factor: 4.823

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.

Authors:  Aygun Babayeva; Elena Ioana Braicu; Jacek P Grabowski; Khayal Gasimli; Rolf Richter; Mustafa Zelal Muallem; Jalid Sehouli
Journal:  Int J Gynecol Cancer       Date:  2018-10       Impact factor: 3.437

5.  [Electron microscopy, cytological, and serological studies on the effect of endoxan on the primary and secondary response of the mouse to sheep erythrocytes].

Authors:  F Gudat; B Keller; R Faes
Journal:  Schweiz Med Wochenschr       Date:  1974-02-23

Review 6.  The 'kiss of death' by dendritic cells to cancer cells.

Authors:  C W Chan; F Housseau
Journal:  Cell Death Differ       Date:  2007-10-19       Impact factor: 15.828

7.  Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins.

Authors:  L Carduner; J Leroy-Dudal; C R Picot; O Gallet; F Carreiras; S Kellouche
Journal:  Clin Exp Metastasis       Date:  2014-06-20       Impact factor: 5.150

Review 8.  Therapeutic potential of cytokine and chemokine antagonists in cancer therapy.

Authors:  Li Yan; G Mark Anderson; Mark DeWitte; Marian T Nakada
Journal:  Eur J Cancer       Date:  2006-03-09       Impact factor: 9.162

Review 9.  Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.

Authors:  C Trumpfheller; M P Longhi; M Caskey; J Idoyaga; L Bozzacco; T Keler; S J Schlesinger; R M Steinman
Journal:  J Intern Med       Date:  2012-01-04       Impact factor: 8.989

Review 10.  Checkpoint inhibitors in ovarian cancer: A review of preclinical data.

Authors:  David W Doo; Lyse A Norian; Rebecca C Arend
Journal:  Gynecol Oncol Rep       Date:  2019-06-18
View more
  5 in total

Review 1.  Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy.

Authors:  David Schweer; Annabel McAtee; Khaga Neupane; Christopher Richards; Frederick Ueland; Jill Kolesar
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

2.  Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses.

Authors:  Denise L Cecil; John B Liao; Yushe Dang; Andrew L Coveler; Angela Kask; Yi Yang; Jennifer S Childs; Doreen M Higgins; Mary L Disis
Journal:  Clin Cancer Res       Date:  2021-09-15       Impact factor: 13.801

3.  Histological changes of cervical tumours following Zanthoxylum acanthopodium DC treatment, and its impact on cytokine expression.

Authors:  Rostime Hermayerni Simanullang; Putri Cahaya Situmorang; Meriani Herlina; Bernita Silalahi; Sarida Surya Manurung
Journal:  Saudi J Biol Sci       Date:  2022-01-04       Impact factor: 4.052

4.  Comparative profiling of immune genes improves the prognoses of lower grade gliomas.

Authors:  Zhiliang Wang; Wen Cheng; Zheng Zhao; Zheng Wang; Chuanbao Zhang; Guanzhang Li; Anhua Wu; Tao Jiang
Journal:  Cancer Biol Med       Date:  2021-10-09       Impact factor: 5.347

Review 5.  Anti-Tumor Effect of Parasitic Protozoans.

Authors:  Haojie Ding; Songrui Wu; Zi Jin; Bin Zheng; Yuan Hu; Ke He; Shaohong Lu; Xunhui Zhuo
Journal:  Bioengineering (Basel)       Date:  2022-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.